Dr Andreas Kany
About
Andreas Kany obtained his PhD at HIPS DDOP for his work on inhibitors of bacterial collagenases. As postdoc, he is currently responsible for in vitro ADME as well as bioassay and formulation development.
2023
Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin a Using a Staphylococcus aureus Infection Model in Zebrafish Embryos
Fries F, Kany A, Rasheed S, Hirsch A, Müller R, Herrmann J (2023)
International journal of molecular sciences 24 (16)DOI: 10.3390/ijms241612791
Selective Activation of TRPC6 Ion Channel by Metallated Type-B Polyprenylated Polycyclic Acylphloroglucinols
Peslalz P, Kraus F, Izzo F, Bleisch A, El Hamdaoui Y, Schulz I, Kany A, Hirsch A, Friedland K, Plietker B (2023)
BookDOI: 10.26434/chemrxiv-2023-6w94r
The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection
Bublitz A, Brauer M, Wagner S, Hofer W, Müsken M, Deschner F, Lesker T, Neumann-Schaal M, Paul L, Nübel U, …, Fuchs T, Strowig T (2023)
Cell Host MicrobeDOI: 10.1016/j.chom.2023.04.003
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle
Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)
Adv. Sci. (Online)DOI: 10.1002/advs.202204443
2022
Screening of Natural Products and Small Molecules Uncovers Novel Coronavirus 1a/1b Frameshifting Inhibitors with Antiviral Properties
Kibe A, Elgaher W, Rand U, Zimmer M, Kany A, Hermann J, Müller R, Cicin-Sain L, Hirsch A, Caliskan N (2022)
SSRN JournalDOI: 10.2139/ssrn.4157446
N-Aryl Mercaptopropionamides as Broad-Spectrum Inhibitors of Metallo-β-Lactamases
Kaya C, Konstantinovic J, Kany A, Andreas A, Kramer J, Brunst S, Weizel L, Rotter M, Frank D, Yahiaoui S, …, Wichelhaus T, Hirsch A (2022)
Journal of medicinal chemistry 65 (5): 3913-3922DOI: 10.1021/acs.jmedchem.1c01755
Inhibitors of Pseudomonas aeruginosa virulence factor LasB
Ducho C, Hartmann R, Haupenthal J, Hirsch A, Kany A, Kaya C, Konstantinovic J, Voos K, Walter I, Yahiaoui S, …, Jumde R, Kiefer A (2022)
Patent A61K31/095; A61K31/10; A61K31/167; A61K31/4184; A61K31/426; A61K31/428; A61K31/4406; A61P31/04; C07C323/60; C07D213/74; C07D235/30; C07D277/46; C07D277/82; C07D333/36; C07F9/38; C07F9/40; (WO2022043322A1)
2021
N-Phenyl-3-Mercaptopropanamide Derivatives as Metallo-Beta-Lactamase Inhibitors for the Treatment of Bacterial Infections
Hartmann R, Konstantinovic J, Haupenthal J, Hirsch A, Kany A, Kaya C, Yahiaoui S, Wichelhaus T, Proschak E (2021)
Patent A61K31/5375; A61P31/04; C07C233/15; C07C233/25; C07C233/33; C07C233/43; C07C233/54; C07C319/02; C07C323/52; C07D295/22; (WO2021191219A1)
N-Phenyl-3-Mercaptopropanamide Derivatives as Metallo-Beta-Lactamase Inhibitors for the Treatment of Bacterial Infections
Hartmann R, Konstantinovic J, Haupenthal J, Hirsch A, Kany A, Kaya C, Yahiaoui S, Wichelhaus T, Proschak E (2021)
Patent A61K31/5375; A61P31/04; C07C233/15; C07C233/25; C07C233/33; C07C233/43; C07C233/54; C07C319/02; C07C323/52; C07D295/22; (WO2021191219A1)
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Substrate-Inspired Fragment Merging and Growing Affords Efficacious LasB Inhibitors
Kaya C, Walter I, Yahiaoui S, Sikandar A, Alhayek A, Konstantinovic J, Kany A, Haupenthal J, Köhnke J, Hartmann R, Hirsch A (2021)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202112295
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369
2020
Micro-rheological properties of lung homogenates correlate with infection severity in a mouse model of Pseudomonas aeruginosa lung infection
Murgia X, Kany A, Herr C, Ho D, Rossi C, Bals R, Lehr C, Hirsch A, Hartmann R, Empting M, Röhrig T (2020)
Scientific Reports 10 (1)DOI: 10.1038/s41598-020-73459-5
N -Aryl-3-mercaptosuccinimides as Antivirulence Agents Targeting Pseudomonas aeruginosa Elastase and Clostridium Collagenases
Konstantinovic J, Yahiaoui S, Alhayek A, Haupenthal J, Schönauer E, Andreas A, Kany A, Müller R, Koehnke J, Berger F, …, Brandstetter H, Hirsch A (2020)
J. Med. Chem. 63 (15): 8359-8368DOI: 10.1021/acs.jmedchem.0c00584
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)
Patent (EP20150119)
2018
Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor
Kany A, Sikandar A, Yahiaoui S, Haupenthal J, Walter I, Empting M, Köhnke J, Hartmann R (2018)
ACS chemical biology 13 (9): 2449-2455DOI: 10.1021/acschembio.8b00257